Summit Therapeutics reports FY2024 net loss $221.3M; HARMONi enrollment complete, data mid-2025

Summit Therapeutics Inc.

2024-FY EPS reported -$0.31

Cash & short-term investments $412.3M at Dec 31, 2024, up from $186.2M at Dec 31, 2023.
GAAP net loss $221.3M ($0.31/share) vs $614.9M ($0.99/share) prior year.
GAAP R&D expense $150.8M vs $59.4M prior year, driven by ivonescimab development.
HARMONi Phase III trial enrollment complete; top-line data expected mid-2025; FDA Fast Track granted.
Pfizer collaboration to evaluate ivonescimab with vedotin ADCs in solid tumors; studies start mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.